In patients with Afib and CAD requiring anti platelet therapy, optimal anticoagulation is unknown. In this cohort, bleeding rates were 14/100 person years with triple therapy (warfarin + 2 anti platelets), ~7-11/100 person years for any dual therapies, and ~6-7/100 person years for any mono therapy. Compared to dual therapy, triple therapy was not associated with a reduction in the combined outcome of CV death, MI, stroke. Triple therapy increases bleeding, without apparent benefit, in patients with Afib and CAD (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.